Insider Selling: Atara Biotherapeutics Inc. (ATRA) CFO Sells $99,200.00 in Stock
Atara Biotherapeutics Inc. (NASDAQ:ATRA) CFO John Mcgrath sold 5,000 shares of the business’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of $19.84, for a total transaction of $99,200.00. Following the completion of the transaction, the chief financial officer now directly owns 91,823 shares of the company’s stock, valued at approximately $1,821,768.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
John Mcgrath also recently made the following trade(s):
- On Wednesday, October 12th, John Mcgrath sold 5,000 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $17.47, for a total transaction of $87,350.00.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) opened at 18.50 on Thursday. The firm’s 50 day moving average is $16.98 and its 200-day moving average is $19.56. Atara Biotherapeutics Inc. has a 12 month low of $12.45 and a 12 month high of $40.80. The firm’s market cap is $533.91 million.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Friday, November 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by $0.10. On average, equities analysts forecast that Atara Biotherapeutics Inc. will post ($3.05) EPS for the current year.
Several large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in shares of Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock worth $1,191,000 after buying an additional 1,900 shares during the period. A.R.T. Advisors LLC boosted its stake in shares of Atara Biotherapeutics by 79.6% in the first quarter. A.R.T. Advisors LLC now owns 63,941 shares of the company’s stock worth $1,216,000 after buying an additional 28,330 shares during the period. Bridger Management LLC acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth about $14,072,000. Bank of New York Mellon Corp boosted its stake in shares of Atara Biotherapeutics by 20.9% in the second quarter. Bank of New York Mellon Corp now owns 99,629 shares of the company’s stock worth $2,243,000 after buying an additional 17,195 shares during the period. Finally, California State Teachers Retirement System boosted its stake in shares of Atara Biotherapeutics by 35.3% in the second quarter. California State Teachers Retirement System now owns 48,704 shares of the company’s stock worth $1,096,000 after buying an additional 12,704 shares during the period. 74.91% of the stock is owned by institutional investors.
ATRA has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 26th. Jefferies Group initiated coverage on shares of Atara Biotherapeutics in a research note on Monday, October 24th. They issued a “buy” rating and a $23.00 target price for the company. Goldman Sachs Group Inc. lowered shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $23.00 to $16.00 in a research note on Thursday, September 15th. Citigroup Inc. upped their target price on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the stock a “sell” rating in a research note on Friday, August 19th. Finally, Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Sunday, November 6th. Three equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $25.86.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.